Compliance certificate under SEBI Regulation 74(5) for Sep 2026 quarter

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Next day

₹169.95

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-1.9% vs market

Pharmaceuticals peers, median of 174sector-1.2%-1.7% vs sector

By the next day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—+0.7—+0.1—

Next day

-2.9-1.0-1.9-1.2-1.7

-7.4-3.6-3.9-2.8-4.6

-12.3-4.5-7.8-3.8-8.6

-17.0-6.8-10.3-5.0-12.0

-17.0-6.4-10.6-3.9-13.1

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Speciality Medicines Limited filed a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2026. The certificate, given by their RTA Skyline Financial Services Private Limited, confirms that no physical share certificates were received for dematerialization of securities during the quarter. This is a standard periodic submission required from listed companies.

Likely market impact

Routine regulatory filing. No material impact on business or shareholders. No physical share certificates pending demat for the quarter.